CD147与亲环素A：一种针对新冠病毒病及相关癌症进展和化疗耐药性的颇具前景的潜在靶向治疗方法。
CD147 and cyclophilin A: a promising potential targeted therapy for COVID-19 and associated cancer progression and chemo-resistance.
作者信息
Bakhtiyari Maryam, Haji Aghasi Ayda, Banihashemi Sara, Abbassioun Arian, Tavakol Chanour, Zalpoor Hamidreza
机构信息
Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.
Network of Immunity in Infection, Malignancy & Autoimmunity (NIIMA), Universal Scientific Education & Research Network (USERN), Tehran, Iran.
出版信息
Infect Agent Cancer. 2023 Apr 4;18(1):20. doi: 10.1186/s13027-023-00501-2.
Coronavirus disease-2019 (COVID-19), as a worldwide serious issue has been shown to lead to progression and poor outcomes in cancer patients. The underlying mechanisms for SARS-CoV-2 infection's adverse effects on cancer patients have not been fully understood. We hypothesized that CD147 and Cyclophilin A (CyPA) not only can play a significant role in infection severity but also can contribute to cancer progression and chemotherapy resistance in cancer patients with COVID-19. In addition, we hypothesized that the expression of both CD147 and CyPA could be increased by Hypoxia-inducible Factor-1 alpha (HIF-1α) activation during hypoxic conditions that occurred during COVID-19. Therefore, this evidence can open a new window in the management of cancer patients during the pandemic and therapeutic approaches targeting CD147 and CyPA could be a potentially promising therapeutic approach for such patients.
2019冠状病毒病（COVID-19）作为一个全球性的严重问题，已被证明会导致癌症患者病情进展和不良预后。严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染对癌症患者产生不利影响的潜在机制尚未完全明确。我们推测，CD147和亲环素A（CyPA）不仅在感染严重程度中起重要作用，而且在COVID-19癌症患者的癌症进展和化疗耐药中也发挥作用。此外，我们推测在COVID-19期间出现的缺氧条件下，缺氧诱导因子-1α（HIF-1α）的激活可增加CD147和CyPA的表达。因此，这一证据可为大流行期间癌症患者的管理打开一扇新窗口，针对CD147和CyPA的治疗方法可能是这类患者潜在的有前景的治疗途径。
Zotero 插件